MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

Search

Pacira Pharmaceuticals Inc-DE

Open

SectorGezondheidszorg

24.74 0.69

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

24.43

Max

25.25

Belangrijke statistieken

By Trading Economics

Inkomsten

-9.7M

-4.8M

Verkoop

12M

181M

Winstmarge

-2.676

Werknemers

788

EBITDA

-4.4M

29M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+7.84% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

76M

1.1B

Vorige openingsprijs

24.05

Vorige sluitingsprijs

24.74

Nieuwssentiment

By Acuity

50%

50%

149 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Pacira Pharmaceuticals Inc-DE Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 apr 2025, 23:45 UTC

Populaire aandelen

Stocks to Watch: CVS Health, UnitedHealth Group, Spire Global, Pacira BioSciences

Peer Vergelijking

Prijswijziging

Pacira Pharmaceuticals Inc-DE Prognose

Koersdoel

By TipRanks

7.84% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 27.25 USD  7.84%

Hoogste 30 USD

Laagste 23 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Pacira Pharmaceuticals Inc-DE - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

5 ratings

2

Buy

2

Hold

1

Sell

Technische score

By Trading Central

24.83 / 26.38Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Weak Bullish Evidence

Sentiment

By Acuity

149 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Pacira Pharmaceuticals Inc-DE

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
help-icon Live chat